ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
Active, not recruiting · NCT05630612 · Registry updated 2026-08-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Skin and Connective Tissue Diseases, Urogenital Diseases, anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune disease, cardiovascular disorder, immune system disorder, kidney disorder, necrotizing vasculitis, skin disorder, skin vascular disease, urinary system disorder, vascular disorder, vasculitis | Active, not recruiting | Phase 2 | 2026-08-26 | NCT05630612 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Travere Therapeutics, Inc. | 10 |
| University of Edinburgh | 108 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Centre for Cardiovascular Science, Queen's Medical Research Institute, 47 Little France Crescent | Edinburgh | United Kingdom | 1 |